{"id":"ramucirumab-paclitaxel","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Leukopenia"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By targeting VEGFR2, ramucirumab reduces the formation of new blood vessels that tumors need to grow. Paclitaxel works by stabilizing microtubules, preventing cell division and ultimately leading to cell death. This combination of mechanisms makes ramucirumab plus paclitaxel effective in treating certain types of cancer.","oneSentence":"Ramucirumab is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis, while paclitaxel is a microtubule inhibitor that blocks cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:15.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic gastric adenocarcinoma, Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06203600","phase":"PHASE2, PHASE3","title":"Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-24","conditions":"Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":224},{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT06346392","phase":"PHASE3","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-04","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":572},{"nctId":"NCT06996782","phase":"PHASE1, PHASE2","title":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":152},{"nctId":"NCT06448754","phase":"PHASE2","title":"Volrustomig Priming Regimens Exploratory Phase II Platform Study","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-27","conditions":"Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT05993234","phase":"","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-12-05","conditions":"HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma","enrollment":257},{"nctId":"NCT07389876","phase":"","title":"Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Gastric Cancer, Second-line Treatment","enrollment":250},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT06043427","phase":"PHASE2","title":"Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-04-16","conditions":"Gastroesophageal Adenocarcinoma","enrollment":168},{"nctId":"NCT03798626","phase":"PHASE1","title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-22","conditions":"Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma","enrollment":167},{"nctId":"NCT04704934","phase":"PHASE3","title":"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2021-05-21","conditions":"Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":490},{"nctId":"NCT06680622","phase":"PHASE2","title":"Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-03-03","conditions":"Metastatic Gastro-esophageal Adenocarcinoma","enrollment":126},{"nctId":"NCT04332367","phase":"PHASE2","title":"Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2020-08-01","conditions":"Non-small Cell Lung Cancer","enrollment":59},{"nctId":"NCT06962137","phase":"PHASE2","title":"Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-12-11","conditions":"Gastric Cancer Adenocarcinoma Metastatic, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","enrollment":100},{"nctId":"NCT03281369","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-13","conditions":"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","enrollment":214},{"nctId":"NCT06251973","phase":"PHASE2","title":"A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-01","conditions":"Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer","enrollment":37},{"nctId":"NCT06675136","phase":"PHASE1","title":"Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-29","conditions":"Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":30},{"nctId":"NCT04205968","phase":"PHASE2","title":"Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2020-06-01","conditions":"Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8","enrollment":94},{"nctId":"NCT03694002","phase":"PHASE2","title":"Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2019-03-20","conditions":"Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma, Recurrent Thymic Carcinoma","enrollment":21},{"nctId":"NCT02597036","phase":"PHASE1","title":"A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2015-11-06","conditions":"Solid Tumors","enrollment":62},{"nctId":"NCT07144995","phase":"","title":"MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-05","conditions":"Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Fruquintinib","enrollment":1143},{"nctId":"NCT05002127","phase":"PHASE2, PHASE3","title":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ALX Oncology Inc.","startDate":"2022-01-15","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma","enrollment":127},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT06038578","phase":"PHASE2","title":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","status":"RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2023-10-04","conditions":"Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":146},{"nctId":"NCT03013218","phase":"PHASE1","title":"A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)","status":"COMPLETED","sponsor":"ALX Oncology Inc.","startDate":"2017-02-03","conditions":"Metastatic Cancer, Solid Tumor, Advanced Cancer","enrollment":174},{"nctId":"NCT04069273","phase":"PHASE2","title":"Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma","status":"RECRUITING","sponsor":"Harry H Yoon","startDate":"2020-12-01","conditions":"Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma","enrollment":58},{"nctId":"NCT06490055","phase":"","title":"Predicting the Efficacy in Advanced Gastric Cancer.","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2018-10-01","conditions":"Gastric Cancer, Chemotherapy Effect, Paclitaxel","enrollment":162},{"nctId":"NCT06490159","phase":"","title":"Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-10-01","conditions":"Gastric Cancer, Chemotherapy-induced Peripheral Neuropathy, Paclitaxel","enrollment":150},{"nctId":"NCT06904300","phase":"PHASE2","title":"Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-15","conditions":"Gastric (Cardia, Body) Cancer","enrollment":110},{"nctId":"NCT05311176","phase":"PHASE2","title":"A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2022-08-17","conditions":"Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma","enrollment":7},{"nctId":"NCT04499924","phase":"PHASE2, PHASE3","title":"Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2021-03-22","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":17},{"nctId":"NCT02307812","phase":"","title":"Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France","status":"APPROVED_FOR_MARKETING","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":""},{"nctId":"NCT03081143","phase":"PHASE2, PHASE3","title":"Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2017-05-10","conditions":"Advanced Gastric or EGJ Cancer","enrollment":429},{"nctId":"NCT06666582","phase":"","title":"Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2015-03-01","conditions":"Gastric Cancer Stage IV, Second-line Treatment, Ramucirumab Paclitaxel","enrollment":185},{"nctId":"NCT04999761","phase":"PHASE1","title":"AB122 Platform Study","status":"RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2021-06-01","conditions":"Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer","enrollment":917},{"nctId":"NCT03760822","phase":"PHASE2","title":"Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-11-16","conditions":"Stomach Cancer, Stomach Neoplasm, Gastric Cancer","enrollment":112},{"nctId":"NCT03921671","phase":"PHASE2","title":"Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)","status":"UNKNOWN","sponsor":"Claudia Proto","startDate":"2018-11-01","conditions":"Thymic Carcinoma, Thymoma","enrollment":60},{"nctId":"NCT04604132","phase":"PHASE1, PHASE2","title":"Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma","status":"TERMINATED","sponsor":"Basilea Pharmaceutica","startDate":"2020-10-06","conditions":"Gastric Adenocarcinoma","enrollment":47},{"nctId":"NCT04660760","phase":"PHASE2","title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2021-06-16","conditions":"Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8","enrollment":116},{"nctId":"NCT06169410","phase":"PHASE4","title":"Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Yang Jianjun, PhD","startDate":"2023-12-30","conditions":"Advanced Gastric Cancer","enrollment":140},{"nctId":"NCT06123494","phase":"PHASE3","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-01-09","conditions":"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":360},{"nctId":"NCT05942573","phase":"PHASE2","title":"Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-12-24","conditions":"Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)","enrollment":107},{"nctId":"NCT03745430","phase":"PHASE1, PHASE2","title":"RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2019-01-29","conditions":"Pancreatic Adenocarcinoma","enrollment":54},{"nctId":"NCT05649163","phase":"","title":"Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy","status":"UNKNOWN","sponsor":"Shen Lin","startDate":"2023-01","conditions":"HER2, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":306},{"nctId":"NCT03762564","phase":"PHASE2","title":"Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2019-03-08","conditions":"Squamous Cell Carcinoma of the Esophagus","enrollment":21},{"nctId":"NCT05190445","phase":"PHASE2","title":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pieris Pharmaceuticals, Inc.","startDate":"2021-11-01","conditions":"HER2-positive Gastric Cancer","enrollment":80},{"nctId":"NCT02317991","phase":"PHASE2","title":"Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2015-05-05","conditions":"Gastroesophageal Cancer","enrollment":65},{"nctId":"NCT04656002","phase":"PHASE2","title":"As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2022-10","conditions":"Gastric Cancer","enrollment":43},{"nctId":"NCT02898077","phase":"PHASE3","title":"A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-03-02","conditions":"Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma","enrollment":440},{"nctId":"NCT05301465","phase":"","title":"Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.","status":"UNKNOWN","sponsor":"University of Pisa","startDate":"2021-11-01","conditions":"Gastric Cancer Stage IV","enrollment":50},{"nctId":"NCT02539225","phase":"PHASE2","title":"A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10-05","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":191},{"nctId":"NCT01515306","phase":"PHASE2","title":"A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07-19","conditions":"Malignant Solid Tumor","enrollment":48},{"nctId":"NCT02970539","phase":"PHASE1","title":"Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers","status":"UNKNOWN","sponsor":"Athenex, Inc.","startDate":"2016-12-08","conditions":"Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer","enrollment":36},{"nctId":"NCT02934464","phase":"PHASE3","title":"Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2016-12","conditions":"Stomach Neoplasms","enrollment":280},{"nctId":"NCT04915807","phase":"","title":"Real-world Data (RWD) of Ramucirumab Plus Paclitaxel","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2021-06","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":222},{"nctId":"NCT04888663","phase":"PHASE1, PHASE2","title":"Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2018-02-13","conditions":"Recurrent/Metastatic Gastric Cancer","enrollment":50},{"nctId":"NCT04192734","phase":"","title":"Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2019-12-18","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":1063},{"nctId":"NCT02730247","phase":"PHASE2","title":"Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Liza Villaruz, MD","startDate":"2017-07-05","conditions":"Non-small Cell Lung Cancer","enrollment":7},{"nctId":"NCT02628951","phase":"PHASE2","title":"Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2016-05-26","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":62},{"nctId":"NCT03193918","phase":"PHASE1","title":"Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma","status":"COMPLETED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2017-04-14","conditions":"Esophagogastric Adenocarcinoma","enrollment":30},{"nctId":"NCT02514551","phase":"PHASE2","title":"A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10-12","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":245},{"nctId":"NCT03704077","phase":"PHASE2","title":"An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2019-10-31","conditions":"Gastric Cancer, Cancer of the Stomach, Stomach Cancer","enrollment":""},{"nctId":"NCT03766607","phase":"PHASE2","title":"Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer","status":"WITHDRAWN","sponsor":"Korean South West Oncology Group","startDate":"2019-09-30","conditions":"Gastric Cancer","enrollment":""},{"nctId":"NCT01170663","phase":"PHASE3","title":"A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Gastric Cancer","enrollment":665},{"nctId":"NCT03966118","phase":"PHASE2","title":"Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma","status":"UNKNOWN","sponsor":"P. C. Thuss-Patience","startDate":"2019-04-01","conditions":"Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma of the Stomach","enrollment":59},{"nctId":"NCT00735696","phase":"PHASE2","title":"A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-01","conditions":"Non Small Cell Lung Cancer","enrollment":41},{"nctId":"NCT01253525","phase":"PHASE1","title":"Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Adenocarcinoma","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ramucirumab+ paclitaxel","genericName":"Ramucirumab+ paclitaxel","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ramucirumab is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis, while paclitaxel is a microtubule inhibitor that blocks cell division. Used for Metastatic gastric adenocarcinoma, Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}